A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for
Por:
Kast R.E., Boockvar J.A., Brüning A., Cappello F., Chang, WW, Cvek B., Dou Q.P., Duenas-Gonzalez A., Efferth T., Focosi D., Ghaffari S.H., Karpel-Massler G., Ketola K., Khoshnevisan A., Keizman D., Magné N., Marosi C., McDonald K., Munoz, M, Paranjpe A., Pourgholami M.H., Sardi I., Sella A., Srivenugopal K.S., Tuccori M., Wang W., Wirtz C.R., Halatsch, ME
Publicada:
1 abr 2013
Categoría:
Oncology
Resumen:
To improve prognosis in recurrent glioblastoma we developed a treatment protocol based on a combination of drugs not traditionally thought of as cytotoxic chemotherapy agents but that have a robust history of being well-tolerated and are already marketed and used for other non-cancer indications. Focus was on adding drugs which met these criteria: a) were pharmacologically well characterized, b) had low likelihood of adding to patient side effect burden, c) had evidence for interfering with a recognized, well-characterized growth promoting element of glioblastoma, and d) were coordinated, as an ensemble had reasonable likelihood of concerted activity against key biological features of glioblastoma growth. We found nine drugs meeting these criteria and propose adding them to continuous low dose temozolomide, a currently accepted treatment for relapsed glioblastoma, in patients with recurrent disease after primary treatment with the Stupp Protocol. The nine adjuvant drug regimen, Coordin
Filiaciones:
Kast R.E.:
IIAIGC Headquarters, Dean of Studies, Burlington, VT, United States
Boockvar J.A.:
Weill Cornell Medical College, NY, United States
Brüning A.:
University of München, München, Germany
Cappello F.:
University of Palermo, Palermo, Italy
Cvek B.:
Palacky University, Olomouc, Czech Republic
Dou Q.P.:
Wayne State University, Detroit, United States
Duenas-Gonzalez A.:
Inst Nacl Cancerol, Inst Invest Biomed UNAM, Mexico City, DF, Mexico
Efferth T.:
Johannes Gutenberg University, Mainz, Germany
Focosi D.:
University of Pisa, Pisa, Italy
Ghaffari S.H.:
Tehran University of Medical Sciences, Tehran, Iran
Karpel-Massler G.:
University of Ulm, Ulm, Germany
Ketola K.:
University of British Columbia, Vancouver, Canada
Khoshnevisan A.:
Tehran University of Medical Sciences, Tehran, Iran
Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
Keizman D.:
Oncology Department, Meir Medical Center, Tel Aviv University, Israel
Magné N.:
Institut de Cancérologie Lucien Neuwirth, Saint-Priest en Jarez, France
Marosi C.:
Medical University of Vienna, Wein, Austria
McDonald K.:
University of New South Wales, Sydney, Australia
Paranjpe A.:
Texas Tech University Health Sciences Center, Amarillo, United States
Pourgholami M.H.:
University of New South Wales, Sydney, Australia
Sardi I.:
Meyer Children's Hospital, Firenze, Italy
Sella A.:
Assaf Harofeh Medical Center, Zerifin, Israel
Srivenugopal K.S.:
Texas Tech University Health Sciences Center, Amarillo, United States
Tuccori M.:
University of Pisa, Pisa, Italy
Wang W.:
University of Wolverhampton, Wolverhampton, United Kingdom
Wirtz C.R.:
University of Ulm, Ulm, Germany
Hybrid Gold
|